161 related articles for article (PubMed ID: 30694216)
41. Who should benefit from the use of alpha-glucosidase inhibitors?
Godbout A; Chiasson JL
Curr Diab Rep; 2007 Oct; 7(5):333-9. PubMed ID: 18173965
[TBL] [Abstract][Full Text] [Related]
42. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
43. Acarbose vs metformin for new-onset type 2 diabetes--author's reply.
Yang W
Lancet Diabetes Endocrinol; 2014 Feb; 2(2):105. PubMed ID: 24622708
[No Abstract] [Full Text] [Related]
44. Effect of acarbose administration on plasma concentrations of zinc and copper in patients with NIDDM.
Song YM; Chen MD; Sheu WH
Kaohsiung J Med Sci; 2000 Apr; 16(4):187-91. PubMed ID: 10933749
[TBL] [Abstract][Full Text] [Related]
45. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.
López-Alvarenga JC; Aguilar-Salinas CA; Velasco-Perez ML; Arita-Melzer O; Guillen LE; Wong B; Brito G; Mercado V; Gómez-Pérez FJ; Rull-Rodrigo JA
Diabetes Obes Metab; 1999 Jan; 1(1):29-35. PubMed ID: 11221809
[TBL] [Abstract][Full Text] [Related]
46. [Diabetes mellitus, cardiovascular sequelae and acarbose. Introductory Address by the German Diabetes Society].
Schatz H
Med Klin (Munich); 2003 Oct; 98 Suppl 1():20. PubMed ID: 14694839
[No Abstract] [Full Text] [Related]
47. [The change of atherogenic index of plasma (AIP) level in type 2 diabetic pedigrees and the response of AIP to Acarbose or Glimepiride in therapy of type 2 diabetes mellitus].
Yang B; Tian H; Ren Y; Tong N; Yu H; Han L; Ran X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Jun; 22(3):560-4. PubMed ID: 16013260
[TBL] [Abstract][Full Text] [Related]
48. [Cardioprotection by acarbose--pro].
Breuer HW
Dtsch Med Wochenschr; 2004 May; 129(20):1155. PubMed ID: 15143459
[No Abstract] [Full Text] [Related]
49. Leukocyte telomere length is inversely associated with post-load but not with fasting plasma glucose levels.
Khalangot M; Krasnienkov D; Vaiserman A; Avilov I; Kovtun V; Okhrimenko N; Koliada A; Kravchenko V
Exp Biol Med (Maywood); 2017 Apr; 242(7):700-708. PubMed ID: 28299976
[TBL] [Abstract][Full Text] [Related]
50. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
Scheen AJ
Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641
[TBL] [Abstract][Full Text] [Related]
51. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
[TBL] [Abstract][Full Text] [Related]
52. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
Göke B;
Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
[TBL] [Abstract][Full Text] [Related]
53. Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study.
Tseng YH; Tsan YT; Chan WC; Sheu WH; Chen PC
Diabetes Care; 2015 Nov; 38(11):2068-74. PubMed ID: 26307605
[TBL] [Abstract][Full Text] [Related]
54. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
55. [Cardioprotection by acarbose--contra].
Kaiser T; Sawicki PT
Dtsch Med Wochenschr; 2004 May; 129(20):1156. PubMed ID: 15143460
[No Abstract] [Full Text] [Related]
56. Effects of Age and Biological Age-Determining Factors on Telomere Length in Type 2 Diabetes Mellitus Patients.
Tariq JA; Mandokhail K; Sajjad N; Hussain A; Javaid H; Rasool A; Sadaf H; Javaid S; Durrani AR
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792881
[No Abstract] [Full Text] [Related]
57. Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation.
Tian J; Li C; Dong Z; Yang Y; Xing J; Yu P; Xin Y; Xu F; Wang L; Mu Y; Guo X; Sun Q; Zhao G; Gu Y; Qin G; Jiang W
Nat Metab; 2023 May; 5(5):896-909. PubMed ID: 37157031
[TBL] [Abstract][Full Text] [Related]
58. Telomere shortening velocity of patients administered with hypnotics is accelerated in a gender-differential manner.
Maeda T; Horiuchi T; Makino N
Can J Physiol Pharmacol; 2021 Mar; 99(3):278-283. PubMed ID: 32687724
[TBL] [Abstract][Full Text] [Related]
59. Association of antidiabetic therapy with shortened telomere length in middle-aged Type 2 diabetic patients.
Al-Thuwaini TM
J Diabetes Metab Disord; 2021 Dec; 20(2):1161-1168. PubMed ID: 34900769
[TBL] [Abstract][Full Text] [Related]
60. Telomere Shortening in Three Diabetes Mellitus Types in a Mexican Sample.
Cuevas Diaz P; Nicolini H; Nolasco-Rosales GA; Juarez Rojop I; Tovilla-Zarate CA; Rodriguez Sanchez E; Genis-Mendoza AD
Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
